Inhibition of the epidermal growth factor receptor (EGFR) by EGCG resulted in potent anti-tumor effects as demonstrated by the inhibition of cell proliferation and migration in non-small cell lung cancer cells [84], reduced colorectal cancer cell growth [85,86], or reduced invasion of breast cancer cells [87]. Here, EGFR is linked to breast carcinoma.